The pivotal Phase 3 trial results show that infigratinib met its primary endpoint, demonstrating a significant change from baseline in annualized height velocity among pediatric patients. Beyond simple height increases, BridgeBio reported that the drug achieved the first statistically significant improvement in body proportionality for those living with achondroplasia. Safety profiles remained robust throughout the trial, with the company stating the treatment was well tolerated and resulted in no serious adverse events or study discontinuations.

The news triggered an immediate rally, sending the company’s stock up 15% to $84.40 before the opening bell. This surge underscores a period of intense momentum for the biotech firm, which has seen its share price more than double over the last 52 weeks as its rare-disease portfolio moves closer to commercialization.

Regulatory Timeline and Pipeline Expansion

Following the positive clinical outcome, the company expects to submit a new drug application for the treatment in the second half of 2024. Management also indicated that the success of the infigratinib program will lead to faster development cycles for other indications. Specifically, BridgeBio plans to accelerate the development of the oral therapy for hypochondroplasia, a related genetic condition that also impacts physical stature.